Mesoblast Completes Patient Recruitment for Chronic Low Back Pain Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy MESO?
Source: Newsfilter
- Trial Recruitment Achieved: Mesoblast announced that its pivotal Phase 3 clinical trial for chronic low back pain has successfully recruited 300 patients, marking a significant milestone in its commercialization plans for rexlemestrocel-L, which is expected to enhance the company's market share in this treatment area.
- FDA Approved Design: The trial is a randomized, placebo-controlled study aimed at confirming the efficacy of rexlemestrocel-L in reducing chronic low back pain, with top-line results anticipated in mid-2027, and positive outcomes will support a regulatory filing with the FDA in Q3 CY2027.
- Significant Market Potential: Chronic low back pain affects over 7 million people in the U.S., with Mesoblast projecting potential peak year revenues exceeding $10 billion, highlighting a substantial commercial opportunity in the non-opioid treatment market.
- Clear Strategic Goals: CEO Silviu Itescu emphasized that the success of this trial will drive the company's goal of delivering a non-opioid, disease-modifying therapy, addressing the significant unmet medical needs of chronic low back pain patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MESO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MESO
Wall Street analysts forecast MESO stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 15.330
Low
35.00
Averages
35.00
High
35.00
Current: 15.330
Low
35.00
Averages
35.00
High
35.00
About MESO
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mesoblast Completes Patient Recruitment for Chronic Back Pain Trial
- Trial Recruitment Achieved: Mesoblast announced that its pivotal Phase 3 clinical trial for chronic low back pain has successfully recruited 300 patients, marking a significant milestone in the commercialization of its proprietary cell therapy rexlemestrocel-L, which is expected to enhance its market competitiveness.
- Efficacy Validation: The trial will compare the pain reduction effects of rexlemestrocel-L against a placebo over 12 months, with earlier trials indicating significant pain and opioid usage reductions over three years, and positive results will support FDA filing.
- Significant Market Potential: Chronic low back pain affects over 7 million people in the U.S., with Mesoblast projecting peak year revenues exceeding $10 billion, highlighting the therapy's substantial market potential and strategic importance.
- Regulatory Advantages: Rexlemestrocel-L has received FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, allowing for priority review upon Biologics License Application submission, which will expedite market access and boost investor confidence.
See More
Mesoblast Completes Patient Recruitment for Chronic Low Back Pain Trial
- Trial Recruitment Achieved: Mesoblast announced that its pivotal Phase 3 clinical trial for chronic low back pain has successfully recruited 300 patients, marking a significant milestone in its commercialization plans for rexlemestrocel-L, which is expected to enhance the company's market share in this treatment area.
- FDA Approved Design: The trial is a randomized, placebo-controlled study aimed at confirming the efficacy of rexlemestrocel-L in reducing chronic low back pain, with top-line results anticipated in mid-2027, and positive outcomes will support a regulatory filing with the FDA in Q3 CY2027.
- Significant Market Potential: Chronic low back pain affects over 7 million people in the U.S., with Mesoblast projecting potential peak year revenues exceeding $10 billion, highlighting a substantial commercial opportunity in the non-opioid treatment market.
- Clear Strategic Goals: CEO Silviu Itescu emphasized that the success of this trial will drive the company's goal of delivering a non-opioid, disease-modifying therapy, addressing the significant unmet medical needs of chronic low back pain patients.
See More
Mesoblast Acquires Exclusive CAR Technology License
- Technology License Acquisition: Mesoblast has acquired an exclusive global license for a chimeric antigen receptor (CAR) technology platform developed by Mayo Clinic through the purchase of a startup, which is expected to significantly enhance the efficacy of its products, particularly in treating ulcerative colitis and Crohn's disease.
- Equity Financing: The acquisition was financed through the issuance of ASX ordinary shares, demonstrating the company's flexibility in capital operations while providing funding support for future technology development, thereby boosting market confidence.
- Enhanced Product Efficacy: Mesoblast indicated that the new CAR technology will improve the effectiveness of its mesenchymal lineage stromal cell (MSC) therapies, potentially offering stronger treatment outcomes for patients and enhancing the company's competitive position in the market.
- Support for Technological Advancement: As part of the deal, Mesoblast is committed to providing in-kind support to further advance the CAR technology and resulting products, reflecting the company's emphasis on innovation and commitment to long-term strategic development.
See More
Mesoblast Acquires CAR Technology Platform for MSC Products
- Technology Acquisition: Mesoblast Limited announced the acquisition of worldwide licensing rights to CAR technology from Mayo Clinic, completing the transaction through the issuance of ASX ordinary shares, aiming to enhance the target specificity and immunomodulation of therapeutic MSC products to improve treatment outcomes for inflammatory and autoimmune diseases.
- Product Development Plans: The company plans to utilize CAR-MSC technology designed to express CD19 on their surface to induce remission in Lupus Nephritis and other B-cell autoimmune diseases, demonstrating its potential in treating complex conditions.
- Support and Collaboration: As part of the acquisition, Mayo Clinic will provide technical support to advance CAR-MSC technology, including the implementation of good manufacturing practice (GMP) activities to ensure product quality and compliance.
- Market Performance: Mesoblast's stock closed at $14.61 on Tuesday, down 0.61%, and further declined to $14.50 in after-hours trading, indicating a cautious market reaction to the acquisition.
See More
Mesoblast Secures Exclusive Global License for CAR Technology
- License Acquisition: Mesoblast Limited announced the acquisition of an exclusive worldwide license for a chimeric antigen receptor (CAR) technology platform, aimed at enhancing the precision and effectiveness of its mesenchymal stem cell (MSC) products by improving target specificity and strengthening immunomodulatory and tissue regeneration properties.
- Integration Plans: The company plans to integrate engineered CAR constructs into its MSC platforms, which already include the first and only FDA-approved MSC product in the United States, thereby significantly improving targeted homing to inflamed tissue and increasing potency in treating tissue-specific inflammatory diseases.
- Intellectual Property Acquisition: Mesoblast obtained exclusive rights to CAR-MSC intellectual property developed at Mayo Clinic through the acquisition of a startup, further advancing the technology and reinforcing its competitive position in next-generation cell therapies.
- Collaborative Support: As part of the agreement, Mayo Clinic will provide in-kind support to further develop the platform and resulting products, including GMP manufacturing activities, ensuring Mesoblast's leading position in the cell therapy sector.
See More
Mesoblast Secures Exclusive Global License for CAR Technology
- License Acquisition: Mesoblast has secured an exclusive global license for a chimeric antigen receptor (CAR) technology platform developed by Mayo Clinic, aimed at enhancing the target specificity and immunomodulatory properties of therapeutic mesenchymal stem cell (MSC) products, thereby boosting efficacy and competitive positioning in the market.
- Enhanced Product Efficacy: By incorporating CAR technology into MSCs, Mesoblast plans to significantly improve targeted homing to inflamed tissues, which is expected to provide more potent treatment options for ulcerative colitis and Crohn's disease, addressing the market's demand for effective therapies.
- Strategic Support from Mayo Clinic: Mayo Clinic will provide technical support, including GMP manufacturing activities, to ensure the successful implementation of the new technology and high-quality production of products, thereby accelerating the time to market and enhancing market trust.
- Sustaining Market Leadership: The CEO of Mesoblast stated that this technology acquisition aligns well with the company's strategy to extend its market leadership, which is expected to drive further development in the treatment of inflammatory diseases and enhance its influence in the global market.
See More
Mesoblast Completes Patient Recruitment for Chronic Back Pain Trial
- Trial Recruitment Achieved: Mesoblast announced that its pivotal Phase 3 clinical trial for chronic low back pain has successfully recruited 300 patients, marking a significant milestone in the commercialization of its proprietary cell therapy rexlemestrocel-L, which is expected to enhance its market competitiveness.
- Efficacy Validation: The trial will compare the pain reduction effects of rexlemestrocel-L against a placebo over 12 months, with earlier trials indicating significant pain and opioid usage reductions over three years, and positive results will support FDA filing.
- Significant Market Potential: Chronic low back pain affects over 7 million people in the U.S., with Mesoblast projecting peak year revenues exceeding $10 billion, highlighting the therapy's substantial market potential and strategic importance.
- Regulatory Advantages: Rexlemestrocel-L has received FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, allowing for priority review upon Biologics License Application submission, which will expedite market access and boost investor confidence.
See More
Mesoblast Completes Patient Recruitment for Chronic Low Back Pain Trial
- Trial Recruitment Achieved: Mesoblast announced that its pivotal Phase 3 clinical trial for chronic low back pain has successfully recruited 300 patients, marking a significant milestone in its commercialization plans for rexlemestrocel-L, which is expected to enhance the company's market share in this treatment area.
- FDA Approved Design: The trial is a randomized, placebo-controlled study aimed at confirming the efficacy of rexlemestrocel-L in reducing chronic low back pain, with top-line results anticipated in mid-2027, and positive outcomes will support a regulatory filing with the FDA in Q3 CY2027.
- Significant Market Potential: Chronic low back pain affects over 7 million people in the U.S., with Mesoblast projecting potential peak year revenues exceeding $10 billion, highlighting a substantial commercial opportunity in the non-opioid treatment market.
- Clear Strategic Goals: CEO Silviu Itescu emphasized that the success of this trial will drive the company's goal of delivering a non-opioid, disease-modifying therapy, addressing the significant unmet medical needs of chronic low back pain patients.
See More
Mesoblast Acquires Exclusive CAR Technology License
- Technology License Acquisition: Mesoblast has acquired an exclusive global license for a chimeric antigen receptor (CAR) technology platform developed by Mayo Clinic through the purchase of a startup, which is expected to significantly enhance the efficacy of its products, particularly in treating ulcerative colitis and Crohn's disease.
- Equity Financing: The acquisition was financed through the issuance of ASX ordinary shares, demonstrating the company's flexibility in capital operations while providing funding support for future technology development, thereby boosting market confidence.
- Enhanced Product Efficacy: Mesoblast indicated that the new CAR technology will improve the effectiveness of its mesenchymal lineage stromal cell (MSC) therapies, potentially offering stronger treatment outcomes for patients and enhancing the company's competitive position in the market.
- Support for Technological Advancement: As part of the deal, Mesoblast is committed to providing in-kind support to further advance the CAR technology and resulting products, reflecting the company's emphasis on innovation and commitment to long-term strategic development.
See More
Mesoblast Acquires CAR Technology Platform for MSC Products
- Technology Acquisition: Mesoblast Limited announced the acquisition of worldwide licensing rights to CAR technology from Mayo Clinic, completing the transaction through the issuance of ASX ordinary shares, aiming to enhance the target specificity and immunomodulation of therapeutic MSC products to improve treatment outcomes for inflammatory and autoimmune diseases.
- Product Development Plans: The company plans to utilize CAR-MSC technology designed to express CD19 on their surface to induce remission in Lupus Nephritis and other B-cell autoimmune diseases, demonstrating its potential in treating complex conditions.
- Support and Collaboration: As part of the acquisition, Mayo Clinic will provide technical support to advance CAR-MSC technology, including the implementation of good manufacturing practice (GMP) activities to ensure product quality and compliance.
- Market Performance: Mesoblast's stock closed at $14.61 on Tuesday, down 0.61%, and further declined to $14.50 in after-hours trading, indicating a cautious market reaction to the acquisition.
See More
Mesoblast Secures Exclusive Global License for CAR Technology
- License Acquisition: Mesoblast Limited announced the acquisition of an exclusive worldwide license for a chimeric antigen receptor (CAR) technology platform, aimed at enhancing the precision and effectiveness of its mesenchymal stem cell (MSC) products by improving target specificity and strengthening immunomodulatory and tissue regeneration properties.
- Integration Plans: The company plans to integrate engineered CAR constructs into its MSC platforms, which already include the first and only FDA-approved MSC product in the United States, thereby significantly improving targeted homing to inflamed tissue and increasing potency in treating tissue-specific inflammatory diseases.
- Intellectual Property Acquisition: Mesoblast obtained exclusive rights to CAR-MSC intellectual property developed at Mayo Clinic through the acquisition of a startup, further advancing the technology and reinforcing its competitive position in next-generation cell therapies.
- Collaborative Support: As part of the agreement, Mayo Clinic will provide in-kind support to further develop the platform and resulting products, including GMP manufacturing activities, ensuring Mesoblast's leading position in the cell therapy sector.
See More
Mesoblast Secures Exclusive Global License for CAR Technology
- License Acquisition: Mesoblast has secured an exclusive global license for a chimeric antigen receptor (CAR) technology platform developed by Mayo Clinic, aimed at enhancing the target specificity and immunomodulatory properties of therapeutic mesenchymal stem cell (MSC) products, thereby boosting efficacy and competitive positioning in the market.
- Enhanced Product Efficacy: By incorporating CAR technology into MSCs, Mesoblast plans to significantly improve targeted homing to inflamed tissues, which is expected to provide more potent treatment options for ulcerative colitis and Crohn's disease, addressing the market's demand for effective therapies.
- Strategic Support from Mayo Clinic: Mayo Clinic will provide technical support, including GMP manufacturing activities, to ensure the successful implementation of the new technology and high-quality production of products, thereby accelerating the time to market and enhancing market trust.
- Sustaining Market Leadership: The CEO of Mesoblast stated that this technology acquisition aligns well with the company's strategy to extend its market leadership, which is expected to drive further development in the treatment of inflammatory diseases and enhance its influence in the global market.
See More
